In the last trading session, 1.58 million shares of the Nektar Therapeutics (NASDAQ:NKTR) were traded, and its beta was 0.59. Most recently the company’s share price was $0.86, and it changed around $0.0 or -0.36% from the last close, which brings the market valuation of the company to $160.16M. NKTR currently trades at a discount to its 52-week high of $1.93, offering almost -124.42% off that amount. The share price’s 52-week low was $0.65, which indicates that the current value has risen by an impressive 24.42% since then. We note from Nektar Therapeutics’s average daily trading volume that its 10-day average is 1.46 million shares, with the 3-month average coming to 1.99 million.
Nektar Therapeutics stock received a consensus recommendation rating of Buy, based on a mean score of 2.11. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 3 recommended NKTR as a Hold, whereas 3 deemed it a Buy, and 1 rated it as Underweight. Nektar Therapeutics is expected to report earnings per share of -0.18 for the current quarter.
Nektar Therapeutics (NASDAQ:NKTR) trade information
Instantly NKTR has showed a red trend with a performance of -0.36% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.9401 on recent trading dayincreased the stock’s daily price by 8.52%. The company’s shares are currently down -7.46% year-to-date, but still down -5.36% over the last five days. On the other hand, Nektar Therapeutics (NASDAQ:NKTR) is -7.68% down in the 30-day period. We can see from the shorts that 6.62 million shares have been sold at a short interest cover period of 2.26 day(s).
The consensus price target as assigned by Wall Street analysts is $18.5, which translates to bulls needing to increase their stock price by 95.35% from its current value. Analyst projections state that NKTR is forecast to be at a low of $6 and a high of $24.
Nektar Therapeutics (NKTR) estimates and forecasts
The year-over-year growth rate is expected to be -36.41%, down from the previous year.
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of 15.61M in revenue for the current quarter. 9 analysts expect Nektar Therapeutics to make 15.7M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 21.64M and 23.49M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -27.88%. Forecasts for the next quarter put sales growth at -33.15%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 25.49%. Nektar Therapeutics earnings are expected to increase by -8.45% in 2025, but the outlook is negative -11.68% per year for the next five years.
Nektar Therapeutics (NASDAQ:NKTR)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.26% of Nektar Therapeutics shares, and 71.87% of them are in the hands of institutional investors. The stock currently has a share float of 72.79%. Nektar Therapeutics stock is held by 180.0 institutions, with DEEP TRACK CAPITAL, LP being the largest institutional investor. By 2024-06-30, it held 8.5599% of the shares, which is about 17.88 million shares worth $22.17 million.
BLACKROCK INC., with 7.7823% or 15.16 million shares worth $18.79 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
